Disc Medicine (IRON) CLO Rahul Khara Buys $24K of Stock
Rahul Khara, Chief Legal Officer at Disc Medicine, purchased 1,649 shares on June 29, 2026, reflecting his confidence in the company.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc. ($IRON), bought 1,649 shares at an average price of $14.69, worth about $24,223.81, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IRON is up 3.4% after 1 week, down 1.1% after 1 month and down 23.7% to date (from the $74.50 close on Jun 29, 2026).
IRON
Disc Medicine, Inc.
Key Points
- On June 29, 2026, Chief Legal Officer Rahul Khara bought 1,649 shares of Disc Medicine, valued at about $24,224, at a price of $14.69 each.
- Disc Medicine currently trades at $73.14, significantly above its 52-week low of $40.00, and analysts have a strong buy outlook with a mean price target of $103.17.
- Khara has been active recently, having made previous purchases totaling 8,501 shares over the past two weeks, signaling strong confidence in the company's future.
Get $IRON trade alerts by text
We text you when insiders, Congress or big funds trade $IRON. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
New Insider Buy by Disc Medicine's Chief Legal Officer
On June 29, 2026, Rahul Khara, the Chief Legal Officer at Disc Medicine, Inc. (NasdaqGM: IRON), bought 1,649 shares for about $24,224. This purchase comes as the stock trades at $73.14, showing a significant interest in the company's prospects. The transaction reflects Khara's confidence as he adds to his holdings in the clinical-stage biopharmaceutical firm, which focuses on developing treatments for serious blood disorders.
Recent Activity of Rahul Khara
This recent buy adds to Khara's previous transactions, including a purchase of 851 shares on June 26, 2026, valued at about $12,501. Just days prior, Khara sold 1,649 shares on the same day as this latest buy, valued at $123,675, suggesting a strategy of balancing his stake in the company.
Analysts Set New Price Targets
Analysts are bullish on Disc Medicine, with firms like Wells Fargo and Wedbush maintaining positive ratings. On September 16, 2026, Wells Fargo kept an Overweight rating with a target of $86.00, up from $79.00. Wedbush reiterated an Outperform rating on September 10, 2026, with a target price of $100.00, indicating a strong belief in the stock's potential. With a mean price target of $103.17, the consensus reflects positive sentiments about Disc Medicine's growth prospects.
How Disc Medicine, Inc. Stock Has Traded
Currently, Disc Medicine is trading at $73.14, well above its 52-week low of $40.00 and approaching its high of $99.50. This position suggests strong market interest, especially as the stock has been fluctuating around its 50-day moving average of $76.60. The company has faced challenges with profitability, reflected in its negative P/E ratio, but the recent insider activity may signal a turnaround in investor confidence.
Recent Earnings
Disc Medicine is set to report its next earnings on November 5, 2026. The company has not reported profits yet, with an EPS of -6.59. Investors are keen to see if future earnings can shift towards profitability, especially given the positive analyst outlook.
Insider Buying and Selling at Disc Medicine, Inc.
Rahul Khara has been active in the market, with several recent transactions. On June 18, 2026, he bought 7,500 shares at $14.69, totaling about $110,175. Combined with his latest acquisition, Khara's commitment to increasing his stake in the company signals a strong belief in Disc Medicine's future.
Closing Thoughts
As Disc Medicine prepares for its next earnings announcement, investors will be watching closely. The recent insider buying, coupled with analyst optimism, may indicate that the company is on the right track. As always, the latest 13F filings provide a snapshot of past holdings and may not represent current positions. Investors should keep an eye on further developments as the company continues to navigate its growth strategy.
Related Filing Alerts
Source: Rahul Khara's Form 4 filing on $IRON (Jun 29, 2026). Find the original filing: IRON Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts